Combination chemotherapy with doxorubicin and lomustine. Treatment of refractory Hodgkin's disease.
Combination chemotherapy with doxorubicin and lomustine. Treatment of refractory Hodgkin's disease.
复制标题
阿霉素和洛莫司汀联合化疗。
DOI：
10.1001/jama.238.15.1659
复制
发表时间：
1977
期刊：
影响因子：
--
通讯作者：
L. Einhorn
中科院分区：
文献类型：
--
作者：
S. Williams;L. Einhorn
Ten patients with advanced Hodgkin's disease refractory to combination therapy with nitrogen mustard, vincristine sulfate, procarbazine, and prednisone (MOPP) were treated with a combination of doxorubicin hydrochloride and lomustine. Toxicity was acceptable. Five patients (50%)attained complete remission (median duration, 15 months). Three patients attained a partial remission (median duration, four months). Survival ranged from three to more than 40 months, and five patients are still alive. One patient remains disease-free after a course of radiation therapy to a site of localized nodal relapse. The doxorubicin-lomustine regimen has induced meaningful remissions in a patient population with very refractory disease.
